"Semiconductor engineering, Biotechnology, Startup ecosystem development, senior management roles in USA/Japan/China/ and India"
Anand was previously Chairman and Managing Director at Cellworks Research India Pvt. Ltd, a company that pioneered the use of Systems biology and semiconductor technologies in creating Directed therapies in Cancer-care. Prior to Cellworks, Anand was the co-founding Managing Director of the India operation of SpinCircuit (acquired by Cadence, 2003) and Magma Design Automation (acquired by Synopsys, 2011). He has management, operations, and business development experience in the US, Europe, China and India regions. Anand received his MS and Ph.D. in Electrical & Biomedical Engineering from George Washington University, Washington DC, and BE (Hons) in ECE from Anna University. He is a member of Eta-Kappa-Nu and Tau-Beta-Pi International Engineering honors societies and is the co-inventor on patents ranging from Satellite communication, Pharmaceuticals to Clean Energy. He is co-founder of India Semiconductor Association (IESA), co-founder of EVA, a healthcare Accelerator, ex-General secretary of ABLE, member of Indo-American Chamber of Commerce, and a Charter member of TiE Bangalore.
Chief Scientific Officer
“Biochemistry, Molecular Biophysics, Systems Biology & Drug Discovery”
Santanu was previously Vice President, Drug Discovery and Industrial Biotechnology at Cellworks Research India Pvt. Ltd where he led the building of the in-silico platform for E.coli and M. tuberculosis and its experimental validation. Prior to this, he was the Principal Research Scientist in AstraZeneca India, where he spent more than 2 decades working in Infectious diseases, with a focus on Malaria and MTB. At AstraZeneca, Santanu scientifically mentored programs across the discovery pipeline and pioneered many ground-breaking concepts such as those of gene and chemical vulnerability. He has served as Principal Investigator in several prestigious research grants from Wellcome Trust, European Union Framework programs and the Department of Biotechnology, India. His current interest is in systems biology and its application in anti-infective drug discovery and in Industrial Biotechnology specifically the interface between insilico and experimental biology. He has published widely and has thirteen international patents. Santanu, received his Ph.D. from Calcutta University in Biophysics in 1981 and was trained as a molecular biologist during his post-doctoral stint in Indian Institute of Science, Baylor College of Medicine USA and Karolinska Institute Sweden.
President – R & D
"Microbiology, Anti-infective Pharmacology, Project Management, Drug Discovery & Development"
Bala was previously Director, Infection Business Unit at Cellworks Research India Pvt. Ltd, where he led the discovery of new combinations for the treatment of tuberculosis. Prior to this, he spent two decades in infection research and anti-bacterial drug discovery at AstraZeneca India Pvt. Ltd, where he established the in vitro and in vivo research for infectious diseases, pioneered the PK/PD science for anti-TB drugs, and led the discovery of a clinical drug candidate for the treatment of tuberculosis. Bala served on the Board of AstraZeneca India Pvt. Ltd as Executive Director. He has served as Principal Investigator in several prestigious research grants from the Wellcome Trust, Bill and Melinda Gates Foundation, European Union Framework program and DBT, Govt. on India. Bala received his Ph.D. as a Marie Christie Kohler fellow from the University of Wisconsin-Madison, USA in Medical Microbiology & Immunology and trained as a Howard Hughes Post-doctoral fellow at the Albert Einstein College of Medicine, NY, USA and has nearly 40 peer-reviewed publications.
M.D., MB ChB, Mpharm.Med, Professor, Pharmacology, University of Pretoria.
Dr. Greeff has been President and Chief Executive Officer of AAA Region of Quintiles Transnational Corp. since 2004. Dr. Greeff served as President of Global Product Development and Chief Executive Officer of Quintiles' global Early Development and Laboratory Services at Quintiles Transnational Corp., since 2002 until September 2004. Before joining Quintiles Transnational Corp., Dr. Greeff founded or co-founded several corporations, including PharmaNet Inc., a retail pharmacy franchise. He is Pharmaceutical industry specialist. Upon joining Quintiles, he served as Medical Director for Quintiles South Africa until January 1999, when he was appointed President of Quintiles Transnational's Africa, India and Australia regions. Latin America was added to his portfolio in 2001. He serves as Chairman of Cenduit, LLC (formerly Cenduit, Inc.). Dr. Greeff serves as Vice Chairman of Quintiles Transnational. He serves as Director at Medwell Ventures Private Limited. He served as a Director of Aspen Pharmacare Holdings Ltd. since 2001 until September 1, 2004. He was elected a Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom in 1997. Dr. Greeff received an M.D. in Psychiatry at the University of Natal. He also received his MpharmMed and MBChB degrees from the University of Pretoria.
VP – Discovery
Shahul is an expert in chemistry and pharmaceutical sciences with nearly 15 years of medicinal chemistry experience in anti-bacterial, anti-malarial and anti-inflammatory drug discovery programs. Shahul was previously Team Leader at AstraZeneca India Pvt. Ltd., where he gained international exposure to drug design, diversity-oriented synthesis, parallel synthesis and new synthetic routes for compounds. Shahul has led several lead generation and lead optimization projects. He has progressed many scaffolds from early hit identification stages to pre-clinical development candidates, combating several challenges such as potency, bacterial cell entry and target engagement, safety and DMPK in parallel, while simultaneously securing intellectual property. Shahul has five patents and has over 20 peer-reviewed publications. Shahul received his doctoral degree in Medicinal Chemistry from BITS Pilani, India.
Vasanthi was previously head of Microbiology at AstraZeneca India, where she led early discovery projects in the search of novel anti-mycobacterial drugs. She jointly led the successful discovery of novel combinations for MDR-TB using an integrated in silico-in vitro- in vivo approach. Vasanthi served as Co-PI on research grants from the Wellcome Trust. She has experience in high through-put cell based screens, assessing vulnerability of drug targets, deciphering mechanisms of action of novel anti-bacterial agents, and setting up in vitro disease models for studying infection. Vasanthi established clinical microbiology based collaborative programs with key reputed hospitals across India. Vasanthi earned her Ph.D. in Microbiology from the Indian Institute of Science.
Nainesh previously led the laboratory research at the Infection Business Unit of Cellworks Research India Pvt. Ltd., located at C-CAMP, National Centre for Biological Sciences, India. He is an experienced Biochemist, Molecular Biologist and a Microbiologist and has worked in the areas of infectious diseases, neurobiology, green-chemistry and biofuels. Nainesh received his Ph.D. at the University of Hamburg, Germany and post-doctoral training at the University of Konstanz, Germany in the area of neuronal development and regeneration. He has a patent and multiple publications in international journals to his credit.
Principal Scientist, Computational Chemistry
Nagakumar previously was with St. Jude Children's Research Hospital, Nanyang Technological University, and GVK Biosciences. Kumar is a Computational Medicinal Chemist with expertise in Structure-/Ligand-based drug discovery and Drug repurposing by applying a variety of methods based on available data such as Consensus Pharmacophore based models, Protein-ligand interaction fingerprints, Molecular docking and clustering of poses, High throughput Short MD simulations for filtering false positives, Virtual screening for scaffold hopping and Evaluation of known Off-targets, Binding free energy calculations for Protein-ligand complexes and Quantitative structure activity relationships (QSAR). Nagakumar received his Ph.D. degree from Gyeongsang National University, Korea in Computer aided drug design.
Computational Biology & Intellectual Property
Ram is the pioneering architect of Cellworks’ Systems Biology computational platform. This platform powers Cellworks' predictive models of human bio-molecular interactions, and is used to design drugs for Cancer, Inflammation, and Infection. He is currently leading the Architecting and implementation of the Bugworks Microbial Platform technology. Ram has been working with cutting edge technologies for over 30 years, and consults in the fields of VLSI, embedded systems and systems biology mathematical modeling. He has also been the Honorary Professor, BITS Pilani, handling IC fabrication technology, VLSI synthesis, DFT and VLSI testing and Analog IC. Ram has mentored over 25 university students through their graduate engineering projects in electrical and electronic systems over the last 10 years. Ram has specialized in Intellectual Property and currently serves as Director, IP at Lakshmikumaran Shridaran Associates law firm. Ram graduated with a Siemens Gold medal as an electrical engineer from IIT, Madras.
Rupanagudi. S. Rao
Preclinical Safety Assessment Drug Discovery & Development
R. S. Rao has over 33 years of experience in safety evaluation, Toxicology & Pathology, Regulatory affairs, drug discovery & development research, having worked in Switzerland, UK, Sweden and India. Rao started his career in 1980, at CIBA-GEIGY/ Novartis, in Switzerland, in the Drug Safety Evaluation and subsequently joined Research Centre (UK.RC), England, U.K, in 1983. As a senior toxicological pathologist at Huntingdon Life Sciences, UK (1983-95) he was successful in designing, conducting (including histopathology slides examination) and evaluating, the preclinical safety of hundreds of candidate drug substances. As chief toxicologist & pathologist at Torrent Pharmaceuticals Ltd (1998 – 2003) Rao designed, conducted, evaluated and reported several toxicity studies. He was successful in establishing, designing (layout sketches)/ constructing, maintaining, managing of preclinical research – toxicology, pharmacology & animal breeding/stock facilities to international guidelines, fulfilling Good Laboratory Practice (GLP) and AAALAC requirements). From 2003 to 2008, Rao worked at AstraZeneca R&D, Sweden, Global Head Safety assessment as a Principal toxicologist/ pathologist. From 2008 to 2013, Rao served as Vice- President and Head of Safety Assessment at Advinus Therapeutics, India. He contributions to the development include drugs such as Voltaren (CIBA-GEIGY,Novartis), AZT- Zidovudine (Welcome), Zantac-Ranitidine Hcl (SKF-GSK), Symbicort, Crestor, Iressa, Losec/Nexium, Pulmocort, Seroquel (AstraZeneca).
Twenty years of experience in Drug Discovery and Development in preclinical ADME,PK, PK/PD, Modelling and Simulation, Preclinical Development (IND enabling), and clinical PK. A year's experience in Discovery and Development of molecular imaging agents for PET/SPECT imaging. Skilled in using modeling and simulation tools like WinNonLin, Simcyp, and Stardrop. Experienced in Managing Outsourced Projects with Contract Research Organizations.
Joined Zeneca in 1994 after a PhD from Imperial College and post-doctoral research at the University of Waterloo-Kitchener, Canada.
His 20 years of experience in medicinal chemistry has been spread across CNS/pain (GPCRs), anti-infectives (enzyme inhibitors) and oncology (kinases, proteases, phenotypic screening, radiometal antibody conjugates).
A secondment into the computational chemistry group led to the development of globally used AZ internal data-mining and exploitation tools. His work at AZ has focused on early stage projects and method development. He is also the author of a medicinal chemistry primer, visiting lecturer at the University of Manchester, and AZ Bangalore.
Dr. Claire Sadler
Dr. Sadler has worked in industry for over 10 years and has been at the forefront of discovery toxicology in both the pharmaceutical and agrichemical industry. Using her broad technical background, scientific knowledge and experience she creates project-specific preclinical packages that address safety issues, with the aim to provide prospective understanding of the major safety risks, thereby influencing chemical design, creating mitigation strategies and expediting progression through GLP-safety studies and initiation of clinical trials. Her expertise includes design and implementation of bespoke preclinical safety packages to identify the safety hazards, assess the safety risks and develop risk mitigation strategies, incorporating in silico, in vitro and in vivo experiments, from target identification through to development.
Dr. Sadler has a proven track record of problem solving in investigative toxicology, elucidating mechanisms of toxicity thereby understanding relevance to humans. Through innovative preclinical experimental design, coupled with extensive understanding of the opportunities and limitations of preclinical models, she has influenced and refined the design of clinical trials to increase efficient execution of the clinical plan.